Outstanding Achievement! JumpCan's Pudilan Xiaoyan Oral Liquid & Tonpei Both Make the List
From March 24 to 29, the 11st Health Industry Ecological Platform (PHCF) was grandly held in Huzhou, Zhejiang Province. The conference brought together tens of thousands of industry professionals who witnessed the announcement of multiple authoritative industry awards. Among them...
On March 23, JumpCan Pharmaceutical and Pharmplus entered into a deep collaboration for the global Class 1 innovative drug Benvitimod Cream (Zelimei), marking its debut launch in Pharmplus's national chain pharmacies. As a non-hormonal dermatological new drug approved simultaneously...
Recently, the final review results of the Jiangsu Association of Chinese Medicine, the Jiangsu Association of Integrative Medicine, and the Jiangsu Association of Acupuncture-Moxibustion’s TCM Science and Technology Awards for 2024–2025 were publicized. The project "Key Technological Innovation...
JumpCan Pharmaceutical (stock code: 600566) recently announced it has formally signed a collaboration agreement with thederma, granting JumpCan Pharmaceutical exclusive commercialization rights for thederma's Benvitimod Cream (Zelimei) in the People's Republic of China (excluding...
Recently, the Center for Drug Reevaluation, NMPA and the National Center for ADR Monitoring, China issued a commendation to units with outstanding performance in 2025. JumpCan Pharmaceutical Group was awarded the title of "Outstanding Enterprise for Drug, Device and Cosmetic...
JumpCan Pharmaceutical (stock code: 600566) and Akeso (stock code: 9926.HK) have officially signed a collaboration agreement. JumpCan Pharmaceutical obtains exclusive commercialization rights for the Class 1 innovative drug Ebronucimab Injection (Yixining) in the People's Republic of China...
JumpCan Pharmaceutical Partners with PrimeGene to Accelerate Commercialization of Class 1 Innovative Drug Pumecitinib
JumpCan Pharmaceutical Group recently announced that it has entered into a collaboration agreement with PrimeGenX Therapeutics Co., Ltd. (hereinafter "PrimeGene") for the Class 1 innovative JAK1/2 inhibitor Pumecitinib (PG-011) Nasal Spray. Under the terms of the agreement, JumpCan...
TJ Biopharma and JumpCan Pharmaceutical Jointly Announce Acceleration of Eftansomatropin Alfa Localization Strategy
Hangzhou, China and Taizhou, China – December 29, 2025 – TJ Biopharma, a fully-integrated biotechnology company focused on drug discovery, clinical development, manufacturing, and collaborative commercialization of innovative biologics in the fields of autoimmune diseases, oncology, and...
JumpCan Pharmaceutical's New Drugs Selected for the First Batch of the Jiangsu Province Innovative Drug and Device Product Catalogue
Recently, the Industry and Information Technology Department of Jiangsu, in conjunction with the Jiangsu Provincial Department of Science and Technology, the Jiangsu Commission of Health, the Jiangsu Healthcare Security Administration, and the Jiangsu Medical Products Administration, released...
Fighting the Flu with a Single Dose — JumpCan's Innovative Anti-Influenza Drug Jikeshu Shines at the VAS Forum
From November 26 to 27, the "China Drugstore Business College VAS Forum" was grandly held in Guangdong Province. Co-organized by the Chain Pharmacy and Clinic Professional Committee of the All-China Federation of Industry and Commerce Medical & Pharmaceutical Industry Chamber, China...